Related Experiment Video
Updated: Aug 20, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Challenges in the assessment of erectile dysfunction and treatment with oral therapies: review with case examples
1Erectile Dysfunction Clinic, Veterans Affairs Medical Center, Minneapolis, Minnesota, USA. jean.lewis@med.va.gov
Purpose:
To review the clinical dimensions, etiology, assessment, and treatment of erectile dysfunction (ED) and to increase awareness of oral therapies for this condition.
Data Sources:
Scientific literature, consensus guidelines, and manufacturers' product information and guidelines.
Conclusions:
A prevalent condition, particularly in middle-aged and elderly men, ED is vastly underreported and undertreated. Oral therapies, including phosphodiesterase type 5 inhibitors, are effective and well tolerated in many patients and represent potential first-line treatments for ED.
Implications For Practice:
ED has been associated with both life-threatening illnesses and reduced quality of life. Improving recognition and treatment of this condition and counseling patients about ED represent important clinical opportunities. A broad and expanding array of ED treatments enable therapy to be individualized to the needs of patients and their partners.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis III: Management